Type your tag names separated by a space and hit enter

tbo-filgrastim

General

Pronunciation:
tbo fil-gras-tim


Trade Name(s)

  • Granix

Pregnancy Category
Category C

Ther. Class.
colony-stimulating factors

Indications

To reduce the duration/severity of neutropenia in patients with non-myeloid malignancies who have received myelosuppressive antineoplastics associated with significant febrile neutropenia.

Action

Binds to granulocyte-colony stimulating factor (G-CSF) receptors and stimulates proliferation of neutrophils.

Therapeutic Effect(s):

Increased neutrophil counts.

Pharmacokinetics

Absorption: 33% absorbed following subcutaneous administration.

Distribution: Recombinant G-CSF products are poorly secreted in breast milk.

Metabolism and Excretion: Unknown.

Half-life: 3.2–3.5 hr.

TIME/ACTION PROFILE (increase in neutrophil count)

ROUTEONSETPEAKDURATION
Subcutwithin 3 days3–5 days16–18 days

Contraindication/Precautions

Contraindicated in:

  • Hypersensitivity, including previous hypersensitivity to filgrastim or pegfilgrastim.

Use Cautiously in:

  • Sickle cell disease
  • OB: Use only if potential benefit justifies potential fetal risk
  • Lactation:Use cautiously
  • Pedi: Safety and effectiveness not established.

Adverse Reactions/Side Effects

Resp: ACUTE RESPIRATORY DISTRESS SYNDROME

GI: SPLENIC RUPTURE

Derm: rash, urticaria

Hemat: SICKLE-CELL CRISIS, leukocytosis

MS: bone pain

Misc: Allergic reactions including anaphylaxis and angioneurotic edema, potential for tumor growth stimulation

* CAPITALS indicate life-threatening.
Underline indicate most frequent.

Interactions

Drug-Drug

Use cautiously with lithium; may have additive effects on neutrophil release.

Route/Dosage

SC: (Adults and Children >18 yr): 5 mcg/kg per day; given no earlier than 24 hr following myelosuppressive chemotherapy; continue until expected neutrophil nadir is passed and neutrophil recovery has occurred.

Availability

Soluion for subcutaneous injection: 300 mcg/0.5 mL single-use prefilled syringe, 480 mcg/0.8 mL single-use prefilled syringe

Assessment

  • Assess for bone pain. Occurs commonly and may require treatment with acetaminophen or NSAIDs.
  • Monitor for signs of enlarged spleen or splenic rupture (upper abdominal pain, left shoulder pain, left upper quadrant pain).
  • Assess for acute respiratory distress syndrome (dyspnea with or without fever, fever, lung infiltrates, respiratory distress). May require discontinuation of tbo-filgrastim.
  • Monitor for signs and symptoms of allergic reactions (rash, urticaria, shortness of breath, wheezing, dizziness, swelling around mouth or eyes, fast heart rate, sweating). Administration of antihistamines, steroids, bronchodilators, and/or epinephrine may reduce severity of reactions. Permanently discontinue tbo-filgrastim if severe reactions occur.

Lab Test Considerations:

Monitor CBC prior to chemotherapy and twice weekly until recovery.

Potential Diagnoses

Implementation

  • Administer no earlier than 24 hr after chemotherapy.
    • Solution should be clear; do not administer solution that is discolored or contains particulate matter. Refrigerate; do not freeze. Do not shake. Syringe is for 1-time use only.
  • SC: Inject into abdomen (except for 2 inch area around navel), front of middle thigh, upper outer area of buttocks, or upper back portion of upper arm. Rotate site daily. Avoid area that is tender, red, bruised, hard, or has scars or stretch marks. Pinch skin gently and administer at 45° angle. Follow manufacturer's instructions for use of safety needle guard device.

Patient/Family Teaching

  • Explain purpose of injection to patient. Advise patient to read Patient Information sheet prior to administration and with each Rx refill in case of changes. Instruct patient and/or caregiver in injection technique and care and disposal of equipment.
  • Advise patient to notify health care professional immediately if signs and symptoms of rupture or enlargement of the spleen, acute respiratory distress syndrome, infection (fever, redness, swelling) or allergic reactions occur.
  • Discuss potential risks and benefits with patients with sickle cell disease prior to administration.
  • Advise patient to notify health care professional if bone pain becomes bothersome.
  • Advise patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications.
  • Advise female patient to notify health care professional if pregnancy is planned or suspected or if breastfeeding.

Evaluation/Desired Outcomes

Decreased incidence of infection in patients who receive bone marrow-depressing antineoplastics.

tbo-filgrastim is a sample topic from the Davis's Drug Guide.

To view other topics, please or purchase a subscription.

Anesthesia Central is an all-in-one web and mobile solution for treating patients before, during, and after surgery. This collection of drug, procedures and test information is derived from Davis’s Drug, MGH Clinical Anesthesia Procedures, Pocket Guide to Diagnostic Tests, and MEDLINE Journals. Learn more.

Citation

Quiring, Courtney, et al. "Tbo-filgrastim." Davis's Drug Guide, 16th ed., F.A. Davis Company, 2019. Anesthesia Central, anesth.unboundmedicine.com/anesthesia/view/Davis-Drug-Guide/110528/all/tbo_filgrastim.
Quiring C, Sanoski CA, Vallerand AH. Tbo-filgrastim. Davis's Drug Guide. 16th ed. F.A. Davis Company; 2019. https://anesth.unboundmedicine.com/anesthesia/view/Davis-Drug-Guide/110528/all/tbo_filgrastim. Accessed April 21, 2019.
Quiring, C., Sanoski, C. A., & Vallerand, A. H. (2019). Tbo-filgrastim. In Davis's Drug Guide. Available from https://anesth.unboundmedicine.com/anesthesia/view/Davis-Drug-Guide/110528/all/tbo_filgrastim
Quiring C, Sanoski CA, Vallerand AH. Tbo-filgrastim [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2019. [cited 2019 April 21]. Available from: https://anesth.unboundmedicine.com/anesthesia/view/Davis-Drug-Guide/110528/all/tbo_filgrastim.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - tbo-filgrastim ID - 110528 A1 - Quiring,Courtney, AU - Sanoski,Cynthia A, AU - Vallerand,April Hazard, BT - Davis's Drug Guide UR - https://anesth.unboundmedicine.com/anesthesia/view/Davis-Drug-Guide/110528/all/tbo_filgrastim PB - F.A. Davis Company ET - 16 DB - Anesthesia Central DP - Unbound Medicine ER -